FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPRO	VAL				
OMB Number:	3235-0287				
Estimated average burd	en				
hours per response:	0.5				

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

					1 2 1-		Nama -	T	draw aw Tw!:		umb al		1-	Dolotic	obio of F	Donosti::	. Dor-	on/o) to !	
1. Name ar		2. Issuer Name and Ticker or Trading Symbol Stellar Biotechnologies, Inc. [SBOT]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)									
HILL DAVID LOUIS						Stemm Disterminion Lieu, Inc. [0501]									rector			10% Ov	
(Last) (First) (Middle) C/O STELLAR BIOTECHNOLOGIES, INC.						3. Date of Earliest Transaction (Month/Day/Year) 03/12/2018									fficer (gi elow)	er (give title v)		Other (s below)	pecify
332 EAST SCOTT STREET																			
			4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable						
(Street)									Ü		`	, ,	Lir	,	e.,		_		
PORT HUENEME CA 93041															filed by One Reporting Person filed by More than One Reporting on				
(City)	(City) (State) (Z																		
		Tab	le I - Nor	n-Deriv	ative	Sec	curitie	s Ac	quired, [Disp	osed c	of, or Be	neficia	lly Ow	ned				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)						ar) E	2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr. 5)				d Sec Ber Ow	mount of curities neficially ned Follo	,	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	nount (A) or (D)		Tra	Reported Transaction(s) (Instr. 3 and 4)				
		Т							uired, Di s, options					/ Own	ed				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Yo	Date,	Code (Ins				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Pric Deriva Securi (Instr.	tive de ty Se 5) Be Ov Fo Re	Number of erivative ecurities eneficially wned ollowing eported ransaction nstr. 4)	e s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable		piration ate	Title	Amount or Number of Shares						
Share Option (Right to Buy)	\$0.84	03/12/2018			A		2,500		(1)	03	/12/2025	Common Shares	2,500	\$0		2,500		D	

Explanation of Responses:

1. Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third immediately, as to one-third on March 12, 2019 and as to the remaining one-third on September 12, 2019.

<u>/s/ Kathi Niffenegger, as</u> <u>Attorney in Fact</u>

03/14/2018

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.